Today's Date: February 8, 2023
League and HealthSparq Partner to Streamline Health Plan Member Support, Reduce Care Costs   •   Research Funding Available for Preeclampsia and Related Pregnancy Disorders   •   Seda North America Awarded Great Place to Work Certification!   •   Kessler Foundation grants nearly $1 million to expand employment opportunities for people with disabilities striving to work in   •   reVolver Podcasts Launches New Shows on Amp, the Live Radio App from Amazon   •   Skillit Releases Inaugural Craft Intelligence Report; Reveals The Top Competitive Markets for Skilled Labor in 2023   •   Fort Health – a New Model to Tackle the Youth Mental Health Crisis in Partnership with Pediatricians   •   Children's Cancer Center Announces Vantagepoint A.I. As February Partner Of The Month   •   Study Shows Novel Flavoprotein Fluorescence Measure is Correlated with Age-Related Macular Degeneration (AMD) Stage   •   Northwestern Mutual Accelerates ESG Momentum in 2022 Sustainability Report   •   HIGHLIGHTS ANNOUNCES LAUNCH OF KINDNESS COLLECTION DESIGNED TO CREATE CURIOUS, CREATIVE, CARING, & CONFIDENT CHILDREN   •   Large Real-World, Multi-Center Study Demonstrates Viz.ai Platform Saves Critical Minutes in Stroke Care   •   STAND UP TO CANCER ANNOUNCES FOUR TEAMS FOCUSED ON DIVERSITY IN EARLY PHASE CANCER CLINICAL TRIALS   •   Aderant Announces Strategic Partnership with Apperio   •   The Future of the Web is Here: Universe Drops Radical New Brand Campaign and Expands Tools to Empower Anyone to Own Their Corner   •   Humana and ChenMed Announce Five-Year Network Agreement   •   CCRM Fertility Announces Two New Office Locations in Washington, D.C. and Rockville, MD   •   INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Plug Power Inc. and Encourages Investors   •   Work-Life Imbalance Cited as Top Stressor for Working Women Today, 24 Seven Report Finds   •   Chrissy Teigen Partners with Cord Blood Registry®
Bookmark and Share

Touchlight receives grant to advance rapid, scalable and thermostable doggybone DNA vaccine platform

HAMPTON, England , November 29 /Businesswire/ - Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, is furthering pre-clinical development of its proprietary doggybone DNA vaccine platform, financed by a new grant received from the Bill & Melinda Gates Foundation.

The program aims to build on evidence that Touchlight’s rapid enzymatic doggybone DNA vaccines can produce strong neutralising antibodies and durable T cell responses following vaccine administration in nanoparticles. As part of the grant, Touchlight will also be investigating the performance of doggybone DNA for therapeutic monoclonal antibody production.

Successful demonstration of the doggybone DNA platform’s effectiveness in DNA vaccine and gene therapy applications has the potential to support the global availability of innovative medicines and to further the application of the doggybone platform in enabling rapid pandemic response.

Karen Fallen, CEO of Touchlight, commented: This grant is further evidence of the potential of our doggybone DNA platform. We are excited to start the program, which could potentially demonstrate that the doggybone DNA platform can support a rapid, scalable, durable and thermostable vaccine solution for future pandemic response.”

Touchlight’s enzymatic approach enables the rapid and scalable DNA manufacture in a significantly smaller footprint than can be achieved with fermentation-based processes. In addition, it eliminates antibiotic-resistance genes that could be present in plasmid DNA, improving safety.

Touchlight’s core focus is to enable genetic medicine by providing Contract Development and Manufacturing (CDMO) services to genetic medicine manufacturers, and doggybone DNA is already widely utilised across the genetic medicine market, in areas such as critical starting material for viral vector and mRNA vaccine production, genome editing and DNA vaccine applications.

About Touchlight

Touchlight is a privately-owned company based in London, U.K., focused on the provision of DNA services and manufacture of enzymatically produced novel DNA formats, such as doggybone DNA (dbDNA™) to enable the development of genetic medicines.

Touchlight DNA Services provide rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences.

Touchlight’s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre-clinical through development and supply, to licencing and tech transfer for use in-house.

Find out more at www.touchlight.com

Follow Touchlight on LinkedIn

Follow @TouchlightDNA on Twitter


STORY TAGS: Other Manufacturing, Medical Devices, Genetics, Manufacturing, Biotechnology, Other Health, Health, Pharmaceutical, General Health, United Kingdom, Europe, Funding, Product/Service,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News